• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Niagen Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    5/7/25 4:01:53 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $NAGE alert in real time by email
    cdxc-20250507
    0001386570FALSE00013865702025-05-072025-05-07
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 7, 2025
    NIAGEN-Bioscience-Logo-Horizontal.jpg

    NIAGEN BIOSCIENCE, INC.
    (Exact name of registrant as specified in its charter)

    Delaware001-3775226-2940963
    (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)

    10900 Wilshire Blvd. Suite 600, Los Angeles, California 90024
    (Address of principal executive offices, including zip code)

    (310) 388-6706
    (Registrant's telephone number, including area code)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, par value $0.001 per share
    NAGE
    The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 2.02. Results of Operations and Financial Condition.

    On May 7, 2025, Niagen Bioscience, Inc. (the “Company”) issued a press release announcing its earnings for the quarter ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

    The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, (the “Securities Act”) or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 7.01. Regulation FD Disclosure.

    On May 7, 2025, the Company released a corporate presentation which it made available on its website. A copy of the corporate presentation is attached hereto as Exhibit 99.2.

    The information in this Item 7.01 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit
    Number
    Description
    99.1
    Press Release dated May 7, 2025
    99.2
    Earnings Presentation of Niagen Bioscience, Inc.
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)





    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    NIAGEN BIOSCIENCE, INC.
    Dated: May 7, 2025
    By:/s/ OZAN PAMIR
    Ozan Pamir
    Chief Financial Officer
    (principal financial officer and duly authorized on behalf of the registrant)

    Get the next $NAGE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NAGE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NAGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Fried Robert N exercised 66,667 shares at a strike of $3.30, increasing direct ownership by 7% to 1,038,981 units (SEC Form 4)

      4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

      4/9/25 7:52:42 PM ET
      $NAGE
      Medicinal Chemicals and Botanical Products
      Health Care

    $NAGE
    SEC Filings

    See more
    • Niagen Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Niagen Bioscience, Inc. (0001386570) (Filer)

      5/7/25 4:01:53 PM ET
      $NAGE
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Niagen Bioscience Inc.

      10-Q - Niagen Bioscience, Inc. (0001386570) (Filer)

      5/7/25 4:01:21 PM ET
      $NAGE
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFA14A filed by Niagen Bioscience Inc.

      DEFA14A - Niagen Bioscience, Inc. (0001386570) (Filer)

      4/29/25 4:19:47 PM ET
      $NAGE
      Medicinal Chemicals and Botanical Products
      Health Care

    $NAGE
    Financials

    Live finance-specific insights

    See more
    • Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

      Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million for the three months ended March 31, 2025 and increased full year 2025 outlook. Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2025. First Quarter 2025 Financial and Recent Operational Highlights Total net sales were $30.5 million, with $21.5 million from Tru Niagen®, up 38%, and 24%, respectively, from the prior year quarter. Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $8.0 million, up 95% YoY. Delivered strong gross margin of 63.4%,

      5/7/25 4:02:00 PM ET
      $NAGE
      Medicinal Chemicals and Botanical Products
      Health Care
    • Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

      Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, May 7, 2025, at 4:30 p.m. ET to discuss its financial results for the first quarter 2025, which ended March 31, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, May 7, 2025. Investor Conference Call: Niagen Bioscience management will host an investor conference call to discuss the first quarter 2025 financial results and provide a general business update on Wednesday, May 7,

      4/28/25 8:34:00 AM ET
      $NAGE
      Medicinal Chemicals and Botanical Products
      Health Care

    $NAGE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

      Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million for the three months ended March 31, 2025 and increased full year 2025 outlook. Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2025. First Quarter 2025 Financial and Recent Operational Highlights Total net sales were $30.5 million, with $21.5 million from Tru Niagen®, up 38%, and 24%, respectively, from the prior year quarter. Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $8.0 million, up 95% YoY. Delivered strong gross margin of 63.4%,

      5/7/25 4:02:00 PM ET
      $NAGE
      Medicinal Chemicals and Botanical Products
      Health Care
    • Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide

      Outperforming NAD+ IV, Niagen IV (patented nicotinamide riboside or NR) provides superior tolerability, a 75% shorter infusion time, and increases NAD+ 20% higher three hours post-infusion Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the continued expansion of its clinical footprint with additional new clinics now offering pharmaceutical-grade Niagen® IV and injections featuring patented nicotinamide riboside. These new providers join a growing network of almost 600 clinics nationwide offering the first-of-its-kind, pharmaceutical-grade NAD-boo

      5/5/25 8:32:00 AM ET
      $NAGE
      Medicinal Chemicals and Botanical Products
      Health Care
    • Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

      Appointment of renowned gerontologist and mitochondrial biology expert underscores Niagen Bioscience's commitment to advancing cutting-edge NAD+ and healthspan research Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, is pleased to announce the appointment of Dr. Pinchas Cohen to its Scientific Advisory Board (SAB).​ Dr. Cohen is an internationally recognized leading expert in healthy aging and mitochondrial biology. He serves as Dean of the University of Southern California (USC) Leonard Davis School of Gerontology and is a Distinguished Professor of Gerontology

      4/29/25 8:32:00 AM ET
      $NAGE
      Medicinal Chemicals and Botanical Products
      Health Care

    $NAGE
    Leadership Updates

    Live Leadership Updates

    See more
    • Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

      Appointment of renowned gerontologist and mitochondrial biology expert underscores Niagen Bioscience's commitment to advancing cutting-edge NAD+ and healthspan research Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, is pleased to announce the appointment of Dr. Pinchas Cohen to its Scientific Advisory Board (SAB).​ Dr. Cohen is an internationally recognized leading expert in healthy aging and mitochondrial biology. He serves as Dean of the University of Southern California (USC) Leonard Davis School of Gerontology and is a Distinguished Professor of Gerontology

      4/29/25 8:32:00 AM ET
      $NAGE
      Medicinal Chemicals and Botanical Products
      Health Care